1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Antisense & RNAi Therapeutics Revenue
• 1.4 Market by Type
  • 1.4.1 Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 RNA interference
  • 1.4.3 SiRNA
  • 1.4.4 MiRNA
  • 1.4.5 Antisense RNA
• 1.5 Market by Application
  • 1.5.1 Global Antisense & RNAi Therapeutics Market Share by Application: 2020 VS 2026
  • 1.5.2 Oncology
  • 1.5.3 Cardiovascular
  • 1.5.4 Renal
  • 1.5.5 Neurodegenerative
  • 1.5.6 Respiratory
  • 1.5.7 Genetic
  • 1.5.8 Infectious Diseases
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Antisense & RNAi Therapeutics Market Perspective (2015-2026)
• 2.2 Global Antisense & RNAi Therapeutics Growth Trends by Regions
  • 2.2.1 Antisense & RNAi Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Antisense & RNAi Therapeutics Historic Market Share by Regions (2015-2020)
  • 2.2.3 Antisense & RNAi Therapeutics Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Antisense & RNAi Therapeutics Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Antisense & RNAi Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Antisense & RNAi Therapeutics Players by Market Size
  • 3.1.1 Global Top Antisense & RNAi Therapeutics Players by Revenue (2015-2020)
  • 3.1.2 Global Antisense & RNAi Therapeutics Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Antisense & RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Antisense & RNAi Therapeutics Market Concentration Ratio
  • 3.2.1 Global Antisense & RNAi Therapeutics Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Antisense & RNAi Therapeutics Revenue in 2019
• 3.3 Antisense & RNAi Therapeutics Key Players Head office and Area Served
• 3.4 Key Players Antisense & RNAi Therapeutics Product Solution and Service
• 3.5 Date of Enter into Antisense & RNAi Therapeutics Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Antisense & RNAi Therapeutics Historic Market Size by Type (2015-2020)
• 4.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Antisense & RNAi Therapeutics Market Size by Application (2015-2020)
• 5.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Antisense & RNAi Therapeutics Market Size (2015-2020)
• 6.2 Antisense & RNAi Therapeutics Key Players in North America (2019-2020)
• 6.3 North America Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
• 6.4 North America Antisense & RNAi Therapeutics Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Antisense & RNAi Therapeutics Market Size (2015-2020)
• 7.2 Antisense & RNAi Therapeutics Key Players in Europe (2019-2020)
• 7.3 Europe Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
• 7.4 Europe Antisense & RNAi Therapeutics Market Size by Application (2015-2020)

8 China

• 8.1 China Antisense & RNAi Therapeutics Market Size (2015-2020)
• 8.2 Antisense & RNAi Therapeutics Key Players in China (2019-2020)
• 8.3 China Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
• 8.4 China Antisense & RNAi Therapeutics Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Antisense & RNAi Therapeutics Market Size (2015-2020)
• 9.2 Antisense & RNAi Therapeutics Key Players in Japan (2019-2020)
• 9.3 Japan Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
• 9.4 Japan Antisense & RNAi Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Antisense & RNAi Therapeutics Market Size (2015-2020)
• 10.2 Antisense & RNAi Therapeutics Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
• 10.4 Southeast Asia Antisense & RNAi Therapeutics Market Size by Application (2015-2020)

11 India

• 11.1 India Antisense & RNAi Therapeutics Market Size (2015-2020)
• 11.2 Antisense & RNAi Therapeutics Key Players in India (2019-2020)
• 11.3 India Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
• 11.4 India Antisense & RNAi Therapeutics Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Antisense & RNAi Therapeutics Market Size (2015-2020)
• 12.2 Antisense & RNAi Therapeutics Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
• 12.4 Central & South America Antisense & RNAi Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Glaxo Smith Kline
  • 13.1.1 Glaxo Smith Kline Company Details
  • 13.1.2 Glaxo Smith Kline Business Overview
  • 13.1.3 Glaxo Smith Kline Antisense & RNAi Therapeutics Introduction
  • 13.1.4 Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2015-2020))
  • 13.1.5 Glaxo Smith Kline Recent Development
• 13.2 Sanofi Aventis / Genzyme
  • 13.2.1 Sanofi Aventis / Genzyme Company Details
  • 13.2.2 Sanofi Aventis / Genzyme Business Overview
  • 13.2.3 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Introduction
  • 13.2.4 Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.2.5 Sanofi Aventis / Genzyme Recent Development
• 13.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
  • 13.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Details
  • 13.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview
  • 13.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Introduction
  • 13.3.4 Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.3.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Development
• 13.4 Arbutus Biopharma Ltd.
  • 13.4.1 Arbutus Biopharma Ltd. Company Details
  • 13.4.2 Arbutus Biopharma Ltd. Business Overview
  • 13.4.3 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Introduction
  • 13.4.4 Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.4.5 Arbutus Biopharma Ltd. Recent Development
• 13.5 Silence Therapeutics
  • 13.5.1 Silence Therapeutics Company Details
  • 13.5.2 Silence Therapeutics Business Overview
  • 13.5.3 Silence Therapeutics Antisense & RNAi Therapeutics Introduction
  • 13.5.4 Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.5.5 Silence Therapeutics Recent Development
• 13.6 Bio-Path Holdings Inc.
  • 13.6.1 Bio-Path Holdings Inc. Company Details
  • 13.6.2 Bio-Path Holdings Inc. Business Overview
  • 13.6.3 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Introduction
  • 13.6.4 Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.6.5 Bio-Path Holdings Inc. Recent Development
• 13.7 Calando Pharmaceuticals
  • 13.7.1 Calando Pharmaceuticals Company Details
  • 13.7.2 Calando Pharmaceuticals Business Overview
  • 13.7.3 Calando Pharmaceuticals Antisense & RNAi Therapeutics Introduction
  • 13.7.4 Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.7.5 Calando Pharmaceuticals Recent Development
• 13.8 ICo Therapeutics
  • 13.8.1 ICo Therapeutics Company Details
  • 13.8.2 ICo Therapeutics Business Overview
  • 13.8.3 ICo Therapeutics Antisense & RNAi Therapeutics Introduction
  • 13.8.4 ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.8.5 ICo Therapeutics Recent Development
• 13.9 Quark Pharmaceuticals
  • 13.9.1 Quark Pharmaceuticals Company Details
  • 13.9.2 Quark Pharmaceuticals Business Overview
  • 13.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Introduction
  • 13.9.4 Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.9.5 Quark Pharmaceuticals Recent Development
• 13.10 Rexhan Pharmaceuticals
  • 13.10.1 Rexhan Pharmaceuticals Company Details
  • 13.10.2 Rexhan Pharmaceuticals Business Overview
  • 13.10.3 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Introduction
  • 13.10.4 Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.10.5 Rexhan Pharmaceuticals Recent Development
• 13.11 Biomarin/Prosensa
  • 10.11.1 Biomarin/Prosensa Company Details
  • 10.11.2 Biomarin/Prosensa Business Overview
  • 10.11.3 Biomarin/Prosensa Antisense & RNAi Therapeutics Introduction
  • 10.11.4 Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 10.11.5 Biomarin/Prosensa Recent Development
• 13.12 Regulus Therapeutics
  • 10.12.1 Regulus Therapeutics Company Details
  • 10.12.2 Regulus Therapeutics Business Overview
  • 10.12.3 Regulus Therapeutics Antisense & RNAi Therapeutics Introduction
  • 10.12.4 Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 10.12.5 Regulus Therapeutics Recent Development
• 13.13 Rxi Pharmaceuticals
  • 10.13.1 Rxi Pharmaceuticals Company Details
  • 10.13.2 Rxi Pharmaceuticals Business Overview
  • 10.13.3 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Introduction
  • 10.13.4 Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 10.13.5 Rxi Pharmaceuticals Recent Development
• 13.14 Silenseed
  • 10.14.1 Silenseed Company Details
  • 10.14.2 Silenseed Business Overview
  • 10.14.3 Silenseed Antisense & RNAi Therapeutics Introduction
  • 10.14.4 Silenseed Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 10.14.5 Silenseed Recent Development
• 13.15 Dicerna Pharmaceuticals
  • 10.15.1 Dicerna Pharmaceuticals Company Details
  • 10.15.2 Dicerna Pharmaceuticals Business Overview
  • 10.15.3 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Introduction
  • 10.15.4 Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 10.15.5 Dicerna Pharmaceuticals Recent Development
• 13.16 Sirnaomics Inc.
  • 10.16.1 Sirnaomics Inc. Company Details
  • 10.16.2 Sirnaomics Inc. Business Overview
  • 10.16.3 Sirnaomics Inc. Antisense & RNAi Therapeutics Introduction
  • 10.16.4 Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 10.16.5 Sirnaomics Inc. Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer

Antisense & RNAi Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Antisense & RNAi Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Glaxo Smith Kline
Sanofi Aventis / Genzyme
Isis Pharmaceuticals/ Ionis Pharmaceuticals
Arbutus Biopharma Ltd.
Silence Therapeutics
Bio-Path Holdings Inc.
Calando Pharmaceuticals
ICo Therapeutics
Quark Pharmaceuticals
Rexhan Pharmaceuticals
Biomarin/Prosensa
Regulus Therapeutics
Rxi Pharmaceuticals
Silenseed
Dicerna Pharmaceuticals
Sirnaomics Inc.

Market segment by Type, the product can be split into
RNA interference
SiRNA
MiRNA
Antisense RNA
Market segment by Application, split into
Oncology
Cardiovascular
Renal
Neurodegenerative
Respiratory
Genetic
Infectious Diseases

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America